Investigators discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. This research appeared in Nature Genetics (2015; doi:10.1038/ng.3217).
Cisplatin is one of the most widely used anticancer drugs and is a mainstay of treatment for children and adults with many types of brain and other solid tumors. But in some patients the drug causes debilitating side effects, including severe hearing loss. The risk factors involved are not completely understood.
“Even for children receiving uniform therapy, there is substantial variability in their hearing damage after cisplatin treatment, and we suspect this has to do with differences in patients’ genetic make-up,” said co-corresponding author Jun J. Yang, PhD, an assistant member of the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital in Memphis, Tennessee.
Researchers checked the DNA of 238 young brain tumor patients for more than 1.7 million common genetic variations. Variations in a gene named ACYP2 were associated with as much as a four-fold greater risk of cisplatin-related hearing loss.
The screening is among the first to survey the genetic landscape for clues to help explain why the risk of cisplatin-related hearing loss varies so widely among patients. St. Jude is a leader in research to improve medication safety and effectiveness. Its research aims to understand how inherited genetic variations affect the way people metabolize and respond to drugs.
“This is an important first step in being able to pinpoint patients who are at higher risk of developing cisplatin toxicity and to learn how to better manage that risk,” said co-corresponding author Clinton Stewart, PharmD, a member of the St. Jude Department of Pharmaceutical Sciences.
The association between the high-risk ACYP2 variants and cisplatin-related hearing loss was confirmed in a separate group of 68 young brain tumor patients. The link was independent of other risk factors for cisplatin-related hearing loss, including patient age and radiation therapy.
Twenty-four of the 306 patients in this study had at least one copy of the high-risk ACYP2 variant. All 24 patients had measurable hearing loss that occurred as early as weeks after beginning cisplatin therapy. Overall, however, the ACYP2 variant explained a relatively small proportion of hearing damage. Just 12.4% of the 194 patients in this study with cisplatin-related hearing loss carried the ACYP2 variant.
“This suggests that other genes also contribute to the risk of hearing loss and are yet to be identified,” Yang said. “Further research is needed to understand how the ACYP2 variations modify the risk facing patients of cisplatin toxicity.”
Such studies could potentially lead to new medications to protect high-risk patients from cisplatin-related toxicity or help identify candidates for intensive monitoring of their hearing. Early intervention could then be offered if problems are identified, Stewart said.
“Our primary goal is to cure children with brain tumors, but we also have a duty to help patients survive with a high quality of life. Hearing loss can have a significant impact on a child’s quality of life, language development, and academic performance,” said co-first author Giles Robinson, MD, an assistant member of the St. Jude Department of Oncology. “There is no easy fix, but the more we know about the risk factors the better we will understand how to use cisplatin.”